Intravenous and oral whole body ketone dosimetry, biodistribution, metabolite correction and kinetics studied by (R)-[1- 11 C]β-hydroxybutyrate ([ 11 C]OHB) PET in healthy humans.
Thien Vinh LuongErik Nguyen NielsenLise FalborgMette Louise Gram KjærulffLars Poulsen TolbodEsben SøndergaardNiels MøllerOle Lajord MunkLars Christian GormsenPublished in: EJNMMI radiopharmacy and chemistry (2023)
C]OHB shows promising potential in providing imaging data on ketone uptake in various physiologically relevant tissues. As a result, it may serve as a safe and non-invasive imaging tool for exploring ketone metabolism in organs and tissues of both patients and healthy individuals. Trial registration Clinical trials, NCT0523812, Registered February 10th 2022, https://clinicaltrials.gov/ct2/show/NCT05232812?cond=NCT05232812&draw=2&rank=1 .
Keyphrases
- clinical trial
- high resolution
- end stage renal disease
- gene expression
- computed tomography
- chronic kidney disease
- ejection fraction
- newly diagnosed
- big data
- phase iii
- prognostic factors
- study protocol
- phase ii
- magnetic resonance
- randomized controlled trial
- fluorescence imaging
- pet imaging
- low dose
- electronic health record
- deep learning
- pet ct